Nurix Therapeutics, Inc.

16.54 USD
-0.05 (-0.30%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Nurix Therapeutics, Inc. stock is up 21.71% since 30 days ago. The next earnings date is Jul 11, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 May’s closed higher than April. In the last 2 Unusual Options Trades, there were 2 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
20 Mar 17:36 18 Oct, 2024 12.50 PUT 100 32
24 Apr 19:15 18 Oct, 2024 12.50 PUT 100 202

About Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies. NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy, is in Phase 1 clinical trials for gynecologic cancers, including ovarian, endometrial, and cervical cancer.

  • Needham
    Tue May 14, 12:03
  • Stephens & Co.
    Tue May 14, 06:01